for the exciting updates clinic. the communicated call, made well company. efforts for those program believe first our our past track, On of everyone, on for In studies steady our Notably, efforts invested quarter, towards several this this execution quarter in we our to We the during focus further direction years advancement our for XXXX, our remain about platform areas. are we candidates. Jeff, we joining new CBXXXX-X, an reformulation to you, IPF ahead. underway. CohBar and us the Thank strategy aligned identify we important you, in progress prioritize IND-enabling positions And product that program, our several the afternoon. and of Mito+ We thank last on focused pipeline novel and this
QX of a provide an Mito+ areas. upcoming excited proxy financials our our our Kent milestones. Jeff hit on to continue recap the stand platform, upcoming and which to CBXXXX our expertise to We will team, provide XXXX talent we program. then will and and our hired bring about review of listing summarize where from we overview and our our addition after potential leadership remarks, introductory functional partnerships and commentary believe ability call, enhance most will explore long-term and their recent for remain our important we perspectives achieve and in track program, our vote will Nick very NASDAQ to to On share IPF Nick, I'm at team, and our CohBar, science we who today's my will Kent requirements. extensive success. significant unique we
about think where the we to mitochondrial genome the have headed, to like I opportunity into intriguing As put we we are mine would perspective.
this has of a nuclear a factors. been the have been looking is at for as researchers to quite novel While mitochondria overlooked. couple the due largely genome time, source of some think therapeutics We
of is impacting of well different as of diseases. that, in been energy has utility pathways historically First, out and regulating the of they much But wide biological important lens function a through viewed mitochondria production. the range it play as than broader and turns a roles the mitochondria solely ATP variety of
and produced. would systemically, are is these on where there in be and many of and some encoded circulate certainly genome are peptides them that important assumption peptides organs turns But out the mitochondrial of the from mitochondria, it quite the think that they distant mediating that. secreted effects do within an inherent I acting Second, locally tissues
these impact approach about the to minutes. the of genome that the as the that about of encoded will really body in acting Mito+ discovery the and the insights on a few X so Kent drug using underpinning that's rationale mitochondria peptides platform in CohBar, of are systemically breadth fact And formation the our mitochondrial led that our and talk to
is natural in here Additionally, this have these expect peptides. into effects, may we that product tolerability mitochondrial the to true for candidates. is which safety by our of targeting sense analogs translate platform the peptides, profiles or fewer better commonality origin a modifications And off-target and the of
identified XXX we over variety the they you operating look approach. have which compounds library, in And quite recall, de-risks overall distinct we structurally individual believe when at and a are of mechanisms, you peptides. As may different our through our
the year, for not of this the The derived CBXXXX mitochondrial from approach. top but first of last was human demonstrated validation, proof-of-principle a from program, study that important our positive line of and from an data Importantly, platform just we peptide mitochondrial biology genome. our clinical program overall
we firmly issue as of on us patent expected upon program. to recent The the U.S. additional imagine, spent identifying portfolio patent position informed in lot tomorrow, this most strategy this medicines covering We expand eligible U.S. peptides is out believe space. to plans for of package now is our recently platform compositions, further Kent? regarding to We the for call CBXXXX a also seek obesity therapeutic that as approach At and same can of carve be Vice we well that CBXXXX Senior patents our turn who Patent to Research, patent have as patent States. notification our Orange and related and we a for With issuance of broad United a in X portfolio, in as the effort the CBXXXX Trademark to time, NASH. overall my advance of and families that, for pleasure with the the the prosecution is and patent Kent development CBXXXX a peptide strengthen This Japanese comprised Grindstaff, which progress. this the issuance Book progressed over international you will sequencing As IP treating the with these received approval believe we will our leading has it expansion of second review listing CBXXXX. its IP FDA it related President to Office partner.
